Similar criteria of FRα positivity were also used in a study of non-small cell lung cancer, in which H-scores ≥ 20 were associated with prolonged PFS (5.5 vs. 3.4 months; HR = 0.61; P = 0.0254) and improved OS (12.1 vs. 6.4 months; HR = 0.57; P = 0.0076).20 Finally, FRα positive expression is associated with better prognosis in a second study of non-small cell lung cancer20,21 and in pancreatic ductal adenocarcinoma.22 Here, FOLR1 is linked to non-small cell lung carcinoma.